A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
Fields of Study & Subjects
CAR-T cell therapy research
Lymphoma Diagnosis and Treatment
Chronic Lymphocytic Leukemia Research
Publication details
- Journal / source
- Vivli
- Publication date
- 27 March 2026
- Language
- EN
- Document type
- Dataset